Physician profile
Rebecca Eia
NPI 1528090859
$4,089.30
in general payments reported to CMS, 2019-2025
30 companies · $951 in 2025
The $951 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $355 · 2021: $530 · 2022: $657 · 2023: $658 · 2024: $532 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.32 | 2019-2025 | Lo Loestrin Fe |
| Astellas Pharma US INC | $564.43 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $422.68 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $346.08 | 2021-2025 | |
| Biogen, INC. | $282.01 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $224.77 | 2019-2025 | Endosee, Paragard T 380a, Mara Console |
| Exeltis, USA INC. | $216.65 | 2019-2025 | Slynd |
| Organon LLC | $170.25 | 2022-2024 | |
| Avion Pharmaceuticals | $143.13 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $128.32 | 2019-2022 | |
| Millicent US INC | $123.77 | 2022-2025 | Intrarosa, Femlyv, Femring |
| Channel Medsystems, INC. | $116.38 | 2022-2024 | |
| Agile Therapeutics, INC. | $86.55 | 2021-2022 | |
| Pfizer INC. | $57.03 | 2019-2025 | |
| Minerva Surgical, INC | $56.91 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $52.35 | 2021-2022 | |
| Lupin INC. | $46.39 | 2019-2020 | |
| Allergan, INC. | $42.69 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $41.69 | 2025 | Myfembree |
| Merck Sharp & Dohme LLC | $40.21 | 2019-2020 | |
| Shield Therapeutics INC | $33.80 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $28.52 | 2019-2023 | Omni Hysteroscope, Myosure Tissue Removal Device |
| Medtronic, INC. | $24.02 | 2022 | |
| Smith+Nephew, INC. | $19.85 | 2024 | Pico |
| Bausch Health US, LLC | $17.60 | 2019 | |
| Exact Sciences Corporation | $16.76 | 2023 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $14.25 | 2020 | |
| Meditrina | $12.85 | 2025 | |
| Amgen INC. | $12.60 | 2020 | |
| Olympus America INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Eia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.